MarketCap
Facebook
X
Telegram
Orgenesis DSO Ratio | ORGS
Annual DSO Ratio Orgenesis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.6 | 12.5 K | 200 | 14 | 155 | 117 | 219 | 80 | 122 | 321 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.5 K | 14 | 1.37 K |
Quarterly DSO Ratio Orgenesis
| 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 52.7 | 90 | 108 | - | 31.9 | 8.62 K | 18.5 K | - | 243 | 227 | 204 | - | 174 | 124 | 58.8 | - | 163 | 161 | 119 | - | 136 | 148 | 199 | - | 10.1 | 22.8 | 32.2 | - | 24.6 | 27.4 | 17 | - | 60.6 | 99.1 | 72.1 | - | 114 | 131 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 K | 10.1 | 1.03 K |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
258 | $ 293.87 | 0.19 % | $ 520 B |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.3 | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
33.4 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Axon Enterprise
AXON
|
134 | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
82.9 | - | - | $ 83.9 M |  Canada |
 |
Liquidia Corporation
LQDA
|
65.5 | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.3 K | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
445 | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
636 | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
83.9 | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
28.7 | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
321 | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
11.6 | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
66.7 | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
80.5 | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
211 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mesoblast Limited
MESO
|
0.00568 | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
130 | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.33 | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
26.2 | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
114 | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
365 | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
61.9 | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
50.9 | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 | - | - | $ 2.02 B | USA |
 |
Intellia Therapeutics
NTLA
|
48.5 | $ 11.18 | -7.72 % | $ 1.21 B | USA |
 |
Novartis AG
NVS
|
0.045 | $ 163.39 | -0.18 % | $ 317 B | Schweiz |
 |
Omeros Corporation
OMER
|
115 | $ 17.3 | -1.48 % | $ 1.1 B | USA |
 |
Puma Biotechnology
PBYI
|
68.5 | $ 8.13 | -3.22 % | $ 407 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
137 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Pfizer
PFE
|
68.1 | $ 29.34 | 0.36 % | $ 167 B | USA |
 |
Prothena Corporation plc
PRTA
|
6.97 | $ 8.56 | -2.51 % | $ 461 M | USA |
 |
Arcus Biosciences
RCUS
|
3.21 | $ 18.66 | -1.56 % | $ 2 B | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
120 | $ 14.9 | -1.03 % | $ 12.4 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
152 | $ 916.16 | -0.41 % | $ 95.8 B | USA |
 |
Фармсинтез
LIFE
|
209 | - | - | - |  Russia |